ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2066

Clinical, Serologic and Morphologic Features of Interstitial Pneumonia with Autoimmune Features (IPAF): A Single Center Experience

Michael Allen1, Emily Press 1, Aditi Mathur 1, Sakshi Dua 2, Maria Padilla 2 and Ioannis Tassiulas 2, 1Icahn School of Medicine at Mt Sinai, New York, 2Icahn School of Medicine, New York

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoimmune diseases and interstitial pneumonia with autoimmune features, interstitial lung disease

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) encompasses a group of disorders that are classified together based on similar clinical, radiographic and pathologic findings. ILD is highly associated with autoimmune connective tissue diseases (CTD), and the diagnosis of ILD necessitates investigation into the possibility of an occult CTD. In a substantial number of cases, this investigation reveals evidence of autoimmunity, serologically, clinically or in both domains, without fulfilling criteria of a specific CTD. This disease category has been termed interstitial pneumonia with autoimmune features (IPAF). The goal of this study was to describe the characteristics of a cohort of ILD patients that fulfil the IPAF criteria.

Methods: The study patients were identified from a Mount Sinai Hospital-Department of Pulmonary Medicine registry of patients with ILD. All of the patients were diagnosed with ILD based on either a high resolution CT (HRCT) of the chest or a lung biopsy. The electronic medical records were reviewed to determine if they fulfilled clinical and/or laboratory IPAF criteria. The radiology report from each patient’s HRCT was reviewed as well as pathology reports from lung biopsies when available. Patients were excluded if they fulfilled classification criteria for a specific autoimmune CTD, or if there was insufficient data to evaluate their case in each of the three domains in which IPAF is assessed (clinical, serologic, morphologic).

Results: Of 429 patients in the ILD registry, 32 met criteria for IPAF. Nineteen were female (59%) and 13 were male (41%). Twenty-nine out of 31 patients (91%), met serologic criteria for IPAF, with the most common being an ANA >1:320 in a diffuse, speckled or homogeneous pattern (16/32). The next most common serologic criterion was anti-CCP positivity (6/32). Other serologic criteria that were present in the study cohort included anti-Ro positivity (4/32), anti-RNP (3/32), ANA< 1:320 in a nucleolar pattern (2/32) and anti-tRNA synthetase (1/32). Fifteen of the 32 patients (47%) met clinical criteria for IPAF. Presence of Raynaud’s phenomenon was the most common (11/32) followed by inflammatory arthritis (5/32), digital edema (2/32) and palmar telangiectasia (2/32). Twenty-eight of the 32 patients (88%) met morphologic criteria for IPAF. Non spesific interstitial pneumonia (NSIP) on HRCT or on biopsy was the most common morphologic criterion (20/32). Other morphologic criteria included unexplained: pleural thickening (3/32), intrinsic airway disease (2/32), pulmonary vasculopathy (1/32), diffuse lymphoplasmacytic infiltrates on lung biopsy (1/32), and pericardial effusion or thickening (1/32).

Conclusion: In a single center, retrospective cohort of patients who meet the IPAF criteria, the great majority of patients have serologic and morphologic findings that support the diagnosis (91% and 88%, respectively). However, less than half of the patients in this cohort (47%), demonstrated clinical features of a systemic autoimmune disease. Identifying patients with IPAF early during the disease course may be important since there is evidence of a favorable response to immunosuppressive therapy.


Disclosure: M. Allen, None; E. Press, None; A. Mathur, None; S. Dua, None; M. Padilla, None; I. Tassiulas, None.

To cite this abstract in AMA style:

Allen M, Press E, Mathur A, Dua S, Padilla M, Tassiulas I. Clinical, Serologic and Morphologic Features of Interstitial Pneumonia with Autoimmune Features (IPAF): A Single Center Experience [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/clinical-serologic-and-morphologic-features-of-interstitial-pneumonia-with-autoimmune-features-ipaf-a-single-center-experience/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-serologic-and-morphologic-features-of-interstitial-pneumonia-with-autoimmune-features-ipaf-a-single-center-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology